therapy without rituximab (15% vs. 37%). 8 Taking the evidence together, rituximab can improve not only the overall survival but also the 1-year survival of patients with BP despite its risk of severe infections.Our data suggest that rituximab improves overall survival and may have a low rate of infectious complications compared with conventional therapy. A prospective randomized clinical trial is needed to validate our observations.